Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
EHA and EBMT join forces in the GoCART coalition to advance cellular therapy in ...
EHA joins EBMT in a newly founded GoCART coalition aimed at positioning Europe in the lead of the global cellular therapy field for hematological diseases. GoCART aims to promote patient access to novel cellular therapies and to contribute health and well-being through innovation by multi-stakeholder collaboration.
CAR T-Cell Research Surges
Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since the first such treatment received approval in 2017. Hundreds of trials are under way, 3 therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma (MM).
Bispecific anti-CD20 and anti-CD19 CAR T Cell Therapy Shows Efficacy in B Cell M...
Nirav N. Shah, MD, an associate professor at the Medical College of Wisconsin, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor (CAR) T cells in a phase 1 dose escalation and expansion trial (NCT03019055) for relapsed B cell malignancies.
The Role of Immunotherapy in the Therapeutic Sequencing for Relapsed/Refractory ...
The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.
Unanswered Questions Remain in DLBCL With Use of CAR T-Cell Therapies
In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.
CRS in CAR-T course freely available on the EHA Campus
The CRS in CAR-T module, part of the 8-course EHA Campus program dedicated to CAR-T cells, is now freely accessible by everyone - even non-EHA members. The course covers all aspects of Cytokine Release Syndrome (CRS), from pathophysiology to appropriate management. As this main complication of CAR-T cell therapy requires a multidisciplinary approach (including non-hematologists like intensivists, cardiologists, and neurologists whose educational needs are addressed in this course), EHA has made this module accessible by everyone.
Off-the-Shelf CAR T-Cell Products Show Potential in DLBCL
Loretta J. Nastoupil, MD, an assistant professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, discusses the use of off-the-shelf chimeric antigen receptor (CAR) T-cell products for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and other cancers.
Patient Perspectives on Cancer Immunotherapy at the 2020 CRI Virtual Immunothera...
At the 2020 CRI Virtual Immunotherapy Patient Summit, three CRI ImmunoAdvocates— cancer veterans treated with immunotherapy —share their experiences with cancer, immunotherapy, health care, and support.
Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma
CAR T-cell therapy is poised to transform the treatment paradigm of relapsed/refractory multiple myeloma now that multiple products are exhibiting high and complete response (CR) rates, said Faiz Anwer, MD, who added that further research may improve safety, prolong responses, and provide insight into resistance mechanisms.
2020 CRI Virtual Immunotherapy Patient Summit: How immunotherapy works against c...
Immunotherapy is transforming treatment for many cancers and shows incredible promise for the future of all cancer care. But what is immunotherapy, and how does it work?